Drugs / Lu AH69593
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07613710 | Jun 2025 → Dec 2026 expected | narcolepsy | H. Lundbeck A/S | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-07-23 | H. Lundbeck A/S | Regulatory Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy lundbeck.com ↗
Lundbeck today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Lu AH69593, the company's lead oral orexin 2 receptor agonist and one of several investigational compounds in Lundbeck’s development portfolio for sleep-wake disorders. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-07-23 | H. Lundbeck A/S | Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy lundbeck.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lu AH69593 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07613710 ↗ |
| Route | Oral | “Participants will receive Lu AH69593 orally for 84 days.” NCT07613710 ↗ |